小摩日前参与药明康德的2025年投资者日，适逢美国总统特朗普宣布计划自10月1日起对进口品牌药及 专利药征收100%关税，除非相关药厂已在美国动工兴建生产设施。小摩预期这次药品关税政策对药明 康德等中国CDMO企业不会构成直接影响，因客户通常负责支付关税，而且药明康德正在扩充其美国产 能，以满足客户对本地化生产的需求。 智通财经APP获悉，摩根大通发布研报称，继续列药明康德(02359)为中国CXO行业的首选股，指出该 公司是中国收入规模最大的合同研究开发与生产组织，看好其业务基本面，认为小分子CRDMO领域竞 争相对温和，同时药明TIDES业务增长动力持续强劲，维持"增持"评级，目标价138港元。 ...

Group 1 - The core viewpoint of the articles highlights the performance and financial metrics of WuXi AppTec, indicating a significant increase in stock price and revenue growth [1][2]. - As of September 29, WuXi AppTec's stock price rose by 2.01% to 104.99 CNY per share, with a market capitalization of 309.87 billion CNY [1]. - The company has experienced a year-to-date stock price increase of 96.76%, while it has seen a decline of 3.40% over the last five trading days [1]. Group 2 - WuXi AppTec's revenue for the first half of 2025 reached 20.799 billion CNY, representing a year-on-year growth of 20.64%, while the net profit attributable to shareholders increased by 101.92% to 8.561 billion CNY [2]. - The company has distributed a total of 14.06 billion CNY in dividends since its A-share listing, with 10.406 billion CNY distributed in the last three years [3]. - As of June 30, 2025, the second-largest shareholder is Hong Kong Central Clearing Limited, holding 302 million shares, an increase of 56.02 million shares from the previous period [3].

该行表示，基于生物学与化学业务前景好过预期，将药明康德2026至2027年收入预测分别上调0.2%及 0.3%，并因研发项目价值提升及生产效率改善调高毛利率预测，相应将每股盈利预测上调0.4%及 0.8%，目标价从123港元上调至130.7港元，重申"买入"评级。 美银证券发表研究报告指，药明康德日前举行投资者日，公司于肿瘤药研发领域自2021年以来在整体活 跃客户(包括药物发现及临床前阶段客户)中的市场份额始终保持在33%，非肿瘤体内药理业务收入今年 上半年亦增长42%。行业价格竞争加剧下，临床前新订单价值仍按年增长14.5%。药明化学业务截至上 半年服务约2550名客户，管理层预期今年收入增长将超过20%。 ...

摩根大通发表研究报告指，日前参与药明康德2025年投资者日，适逢美国总统特朗普宣布计划自10月1 日起对进口品牌药及专利药征收100%关税，除非相关药厂已在美国动工兴建生产设施。摩通预期今次 药品关税政策对药明康德等中国CDMO企业不会构成直接影响，因客户通常负责支付关税，而且药明康 德正在扩充其美国产能，以满足客户对本地化生产的需求。 摩通继续列药明康德为中国CXO行业的首选股，指出该公司是中国收入规模最大的合同研究开发与生 产组织，看好其业务基本面，认为小分子CRDMO领域竞争相对温和，同时药明TIDES业务增长动力持 续强劲，维持"增持"评级，目标价138港元。 ...

2025 年 9 月 29 日 招银国际环球市场 | 市场策略 | 招财日报 每日投资策略 行业、公司点评 全球市场观察 招银国际研究部 邮件：research@cmbi.com.hk | 环球主要股市上日表现 | | | | | --- | --- | --- | --- | | | 收市价 | | 升跌（%） | | | | 单日 | 年内 | | 恒生指数 | 26,128 | -1.35 | 30.25 | | 恒生国企 | 9,303 | -1.49 | 27.62 | | 恒生科技 | 6,195 | -2.89 | 38.65 | | 上证综指 | 3,828 | -0.65 | 14.21 | | 深证综指 | 2,471 | -1.54 | 26.22 | | 深圳创业板 | 3,152 | -2.60 | 47.16 | | 美国道琼斯 | 46,247 | 0.65 | 8.70 | | 美国标普 500 | 6,644 | 0.59 | 12.96 | | 美国纳斯达克 | 22,484 | 0.44 | 16.43 | | 德国 DAX | 23,739 | 0.87 | 19.24 ...

2000 年美国《时代周刊》曾以阿尔茨海默病科学研究作为封面故事。彼时，这种重大神经退行性疾病的研究仍处在起步阶段。 25 年后，几经沉浮、不乏质疑，阿尔茨海默病治疗已频频迎来历史性突破，多款疾病修饰疗法问世，血液检测辅助诊断成为现实，管线储备持续 扩充。 真正有价值的科学成果，总能 历经 时间的考验，最终改变世界。 企业亦然。那些 具备独特能力、 不断自我迭代的公司，才能 不断跨越周期发展，始终 站稳脚跟。药明康德正是这样的代表。 从一间 650 平方米的实验室起步， 到如今布局全球 20 多个运营基地、携手数千家合作伙伴，药明康德即将迎来 25 周年。 25 年来，药明康德 以质量、速度和能力规模不断赢得客户的信任 ，收获业绩的持续高速增长。 在周期波动的行业环境下，药明康德展现出少有 的韧性与确定性。 9 月 25 日，在药明康德 2025 年投资者开放日上，药明康德的高管分享传递出一个信息：面向未来，在时代的变幻中，这家公司依然有信心，为 产业创造价值，向投资人回报价值。 这样的底气，源于对行业趋势、对独特业务模式、对管理精度的 "确定"。 分水岭已至，创新 需求推动全球 CXO 市场扩容 此次投资者 ...

Summary of WuXi AppTec Investor Day and Related Insights Company Overview - **Company**: WuXi AppTec - **Industry**: Contract Development and Manufacturing Organization (CDMO) - **Market Position**: Largest CDMO in China with a 28% market share in the total outsourcing market as of 2022 and a 16% global market share in small-molecule new drug projects under clinical development [doc id='8'][doc id='15'] Key Insights from the Investor Day - **Impact of US Pharma Tariff**: The recently announced 100% tariff on branded drug imports by the US is not expected to directly impact WuXi AppTec, as CDMO customers typically bear the tariff costs. The company is expanding its US manufacturing capacity to meet local demand [doc id='2'][doc id='5'] - **R&D Capabilities**: Management highlighted WuXi AppTec's strong R&D capabilities, operational efficiency, and cost-effectiveness, although specific future growth targets were not provided [doc id='2'] - **Emerging Modalities**: The company is expanding its capabilities in emerging modalities such as peptides, oligonucleotides, and complex conjugates, which are crucial for future growth [doc id='2'] Financial Performance and Growth Drivers - **TIDES Business Growth**: WuXi AppTec's TIDES business (focused on peptides and oligonucleotides) is projected to surpass RMB 10 billion in revenue by 2025, with over 80% year-over-year revenue growth [doc id='6'] - **Project Contributions**: "R" stage projects contribute approximately 70% of new customers, with a 40% penetration rate in the small molecule "R" stage market. The average molecular weight of drug candidates has increased by 14% over the past five years [doc id='5'] - **Operational Excellence**: The company has implemented a sophisticated operational excellence program, achieving a gross margin of 45% and a net profit margin of 30%. Facility utilization has improved from 60% to 72%, and new plant ramp-up times have been reduced from two years to two months [doc id='7'] Strategic Initiatives - **Global Expansion**: WuXi AppTec is focusing on global expansion, with over 85% of capital expenditure directed towards high-demand, late-stage development and manufacturing capabilities. Major projects in the US and Singapore are part of this strategy [doc id='7'] - **Geopolitical Risk Mitigation**: The expansion into the US is also a strategic move to mitigate geopolitical risks and meet client demand for localized supply chains [doc id='7'] Valuation and Price Target - **Price Target**: The price target for WuXi AppTec is set at RMB 138.00 for June 2026, based on a discounted cash flow (DCF) valuation with a terminal growth rate of 3.0% and a weighted average cost of capital (WACC) of 9.8% [doc id='9'] - **Valuation Metrics**: The DCF analysis indicates an equity value per share of RMB 138, with significant upside potential from current levels [doc id='10'] Risks and Considerations - **Downside Risks**: Key risks include geopolitical tensions, competition from overseas CDMOs, product development failures, and potential losses in biotech investments [doc id='12'][doc id='19'] - **Upside Risks**: Potential improvements in the geopolitical environment, earlier-than-expected biotech funding growth, and faster project growth could positively impact the company's performance [doc id='13'] Conclusion WuXi AppTec remains a strong player in the CDMO space, with robust growth prospects driven by its operational excellence, expanding capabilities in emerging modalities, and strategic global expansion efforts. The recent US pharma tariff is not expected to hinder its growth trajectory, making it a compelling investment opportunity in the healthcare sector.

Summary of Wuxi Apptec 2025 Investor Day Takeaways Company Overview - **Company**: Wuxi Apptec - **Industry**: Pharmaceutical R&D services - **Market Position**: Largest chemical drug contract research, development, and manufacturing organization (CRDMO) in China - **Public Listing**: Listed on both the Shanghai Stock Exchange and Hong Kong Stock Exchange since 2018 [11][26] Key Financial Guidance - **2025 Revenue Guidance**: Rmb42.5-43.5 billion, with an improving non-IFRS net profit margin [2][5] - **Revenue Growth**: Expected recovery in global R&D demand, particularly following Fed rate cuts [2] Growth Drivers - **TIDES Growth**: TIDES remains a key driver for Wuxi Chemistry, with a revenue target of +80% YoY for 2025 [3] - **Wuxi Chemistry Revenue Target**: Projected to grow over 20% YoY, indicating a strong operational performance [3] - **Operational Efficiency**: Enhanced efficiency through in-house developed software, reducing new plant ramp-up time from 22.6 months to 2.4 months and increasing utilization rates to 72% in H125 from 60% in 2020 [3] Market Opportunities - **Global Licensed Synthetic Drugs**: Wuxi Apptec serviced 29% (62) of the global licensed synthetic drugs in 2024-H125, achieving a 100% project retention rate [2] - **New Plant Operations**: Plans to operate the first plant in Singapore by January 2027 and a US site by late 2026 for solid oral formulation drug products [3] R&D Demand Recovery - **Preclinical Services Growth**: New orders for preclinical services grew 14.5% YoY in H125, with the EU leading at +30.7%, followed by the US at +19.9% and China at +11.6% [4] - **Long-term Growth Potential**: Strong growth in complicated modalities is expected to fuel Wuxi Apptec's growth in the long term [4] Valuation and Investment Rating - **Price Target**: HK$136.10, implying a 24.1x 2026E PE [5] - **Current Price**: HK$109.20 as of September 24, 2025 [7] - **Investment Rating**: Buy rated, with a forecast stock return of 26.2% [10] Financial Metrics Overview - **Revenue Projections**: Expected revenues to grow from Rmb39.355 billion in 2022 to Rmb43.979 billion in 2025E [6] - **Net Earnings**: Projected net earnings to increase from Rmb8.814 billion in 2022 to Rmb15.284 billion in 2025E [6] - **EBIT Margin**: Expected to improve from 25.1% in 2022 to 35.5% in 2025E [6] Risks and Considerations - **Key Risks**: Potential project delays or failures, geopolitical issues, and lower-than-expected R&D spending by pharmaceutical companies [12] Upcoming Catalysts - **Catalyst Date**: October 31, 2025, with a focus on Q325 results, TIDES growth, and recovery signals in domestic CRO services [14]

2025 年 9 月 29 日 招银国际环球市场 | 睿智投资 | 公司更新 药明康德 (603259 CH) 药明康德 (603259 CH) - 投资者日：TIDES 势头延续，早期研发初现回暖 药明康德举办了投资者日活动，我们认为此次会议的要点如下：1）TIDES 业务 发展势头不变，产能扩张迅速、管线储备丰富；2）早期研发显现进一步复苏的 信号，将拉动占公司总收入约 1/3 的早期业务收入的增长；3）精细化运营助力 公司在面对宏观不确定性以及进行全球产能扩张的同时保持有韧性的盈利能力。 | 财务资料 | | | | | | | --- | --- | --- | --- | --- | --- | | (截至 12 月 31 日) | FY23A | FY24A | FY25E | FY26E | FY27E | | 销售收入 (百万人民币) | 40,341 | 39,241 | 43,981 | 50,952 | 58,999 | | 同比增长 (%) | 2.5 | (2.7) | 12.1 | 15.9 | 15.8 | | 调整后净利润 (百万人民币) | 10,854 | 10,583 | ...

报告指，药明康德举办了投资者日活动，该行认为此次会议的要点如下：1)TIDES业务发展势头不变， 产能扩张迅速、管线储备丰富;2)早期研发显现进一步复苏的信号，将拉动占公司总收入约三分之一的 早期业务收入的增长;3)精细化运营助力公司在面对宏观不确定性以及进行全球产能扩张的同时保持有 韧性的盈利能力。 智通财经APP获悉，招银国际发布研报称，预计药明康德(02359)在2025/26/27年持续经营收入同比增长 16%/15.9%/15.8%，经调整净利润同比增长16.2%/17.6%/16.4%。 ...